6533b855fe1ef96bd12afff2
RESEARCH PRODUCT
Long-Term Follow-Up of Patients with Chronic Hepatitis C after Interferon-Alpha Treatment
G. TeuberG. GerkenK. H. Meyer Zum BüschenfeldeHans-peter Dienessubject
AdultMalemedicine.medical_specialtyLong term follow upmedicine.medical_treatmentAlpha interferonHepacivirusGastroenterologyVirusChronic hepatitisInterferonInternal medicinemedicineHumansProspective StudiesInterferon alfaAgedbusiness.industryGastroenterologyInterferon-alphaImmunotherapyMiddle AgedHepatitis CChronic DiseaseImmunologyRNA ViralFemaleViral diseasebusinessFollow-Up Studiesmedicine.drugdescription
In this study, 72 patients with chronic hepatitis C virus (HCV) were followed prospectively for a mean period of 27 months after interferon treatment. Fifty-seven percent (20/35) of the patients with complete response, 18/20 with HCV-RNA-negative serum, had a sustained biochemical remission. Reactivation was seen in 43% of these patients after a mean follow-up of 7.3 months. A late relapse after more than 12 months of follow-up occurred in only 2/15 patients. Patients with a long-term complete response had significantly lower pretreatment serum HCV RNA levels than complete responders with relapse (106,239 vs. 345,649 mEq/ml, p = 0.0213). A delayed sustained biochemical remission was seen in 3/37 patients with partial or no response. Thus, long-term response is achieved in 32% of the patients treated with interferon, clearly associated with a suppression of serum HCV RNA. Patients with normal ALT values and undetectable levels of HCV RNA for more than 12 months of follow-up may usually be considered as sustained responders. Thus, for the first time, the pretreatment HCV RNA level in serum was identified as predictive of long-term response.
year | journal | country | edition | language |
---|---|---|---|---|
1996-11-01 | Digestion |